Brief Communications
Nature 440, 1123 (27 April 2006) | doi:10.1038/4401123a; Received 18 October 2005; Accepted 28 March 2006
There is a Brief Communications Arising (21 September 2006) associated with this document.
There is a Brief Communications Arising (21 September 2006) associated with this document.
Gene therapy: Therapeutic gene causing lymphoma
Niels-Bjarne Woods1, Virginie Bottero1, Manfred Schmidt2,3, Christof von Kalle2 and Inder M. Verma1
The development of T-cell leukaemia following the otherwise successful treatment of three patients with X-linked severe combined immune deficiency (X-SCID) in gene-therapy trials using haematopoietic stem cells1 has led to a re-evaluation of this approach2. Using a mouse model for gene therapy of X-SCID, we find that the corrective therapeutic gene IL2RG itself can act as a contributor to the genesis of T-cell lymphomas, with one-third of animals being affected. Gene-therapy trials for X-SCID, which have been based on the assumption that IL2RG is minimally oncogenic3, 4, 5, 6, 7, may therefore pose some risk to patients.
-
Laboratory of Genetics, The Salk Institute for Biological Studies, La Jolla, California 92037, USA
Email: verma@salk.edu - National Center for Tumor Diseases Heidelberg and Department of Translational Oncology, German Cancer Research Center, Otto-Meyerhof-Zentrum Im Neuenheimer Feld 350, 69120 Heidelberg, Germany
- Department of Internal Medicine I, University Hospital, 79106 Freiburg, and Institute of Molecular Medicine and Cell Research, Albert-Ludwigs-University, 79104 Freiburg, Germany
Received 18 October 2005 | Accepted 28 March 2006 |
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated.
RESEARCH
Gene therapy Is IL2RG oncogenic in T-cell development?: X-SCID transgene leukaemogenicity (reply)Nature Brief Communication (21 Sep 2006)
Gene therapy X-SCID transgene leukaemogenicityNature Brief Communication (21 Sep 2006)
See all 4 matches for Research